anti-FGFR2b/topoisomerase-1 inhibitor antibody-drug conjugate BG-C137

{
  "id": "MLC-T-ONC-010655",
  "term": "anti-FGFR2b/topoisomerase-1 inhibitor antibody-drug conjugate BG-C137",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the fibroblast growth factor receptor 2b (FGFR2b; fibroblast growth factor receptor 2 isoform IIIb; FGFR2 IIIb) conjugated to an as of yet undisclosed topoisomerase-1 inhibitor, with potential antineoplastic activity. Upon administration of anti-FGFR2b/topoisomerase-1 inhibitor ADC BG-C137, the antibody moiety targets and binds to FGFR2b-expressing tumor cells. Upon binding and internalization, the topoisomerase-1 inhibitor is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing FGFR2b. FGFR2b is overexpressed on certain tumor cell types.",
  "synonyms": [
    "anti-FGFR2b ADC BG-C137",
    "anti-FGFR2b/Top-1i inhibitor ADC BG-C137",
    "FGFR2b-targeted ADC BG-C137"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-fgfr2b-topoisomerase-1-inhibitor-antibody-drug-conjugate-bg-c137/"
}